Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding her Department has given to Stonewall since 2019.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Our financial records show a total sum of £6,000 paid to Stonewall between the years 2019 to 2020, as part of the Diversity Champions annual membership. This is broken down into £3,000 between 1 January 2019 and 31 December 2019, and £3,000 between 1 January 2020 and 31 December 2020. As of February 2021, the Department’s membership with Stonewall lapsed, with no further payments made from 2021 to date.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the implications for her policies of research by Professor Martin Schwendler and Dr Chiara Herzog on changes to epithelial cells caused by vaping.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Vaping is never recommended for children, and carries the potential harms of future addiction while their lungs and brains are still developing. The health advice is clear, vapes can be an effective tool to help smokers quit, but young people and those who have never smoked should not vape, or be encouraged to vape.
As stated by Cancer Research UK, this study contributes to our understanding of e-cigarettes, also known as vapes, but does not show that e-cigarettes cause cancer. Decades of research has proven the link between smoking and cancer, and studies have so far shown that e-cigarettes are far less harmful than smoking, and can help people quit. This paper does, however, highlight that vapes are not risk-free, and so we need additional studies to uncover their potential longer-term impacts on human health.
Asked by: Neil O'Brien (Conservative - Harborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of her Department's drug strategy on the number of people who are in (a) drug and (b) alcohol treatment.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
By January 2024 there were an additional 9,907 adults in treatment for drugs and 9,908 adults in treatment of alcohol problems, when compared to the start of the drugs strategy in March 2022. Additionally, over the same period, there were an extra 2,650 children and young people receiving specialist support for drug and alcohol problems.
The number of prison leavers referred to community-based drug and alcohol services engaging in treatment within three weeks of release has risen to a high of 52% in January 2024, up from 36% in March 2022. Additionally, in 2023/24 we engaged over 10,000 people who sleep rough, or who are at risk of sleeping rough, in support for rough sleeping drug and alcohol treatment teams, with over 9,000 people supported by these specialist teams while in treatment.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of banning the use of vapes in (a) public spaces, (b) bars and (c) vehicles with child passengers.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Vaping can be an effective tool for adult smokers to quit smoking. However, the health advice is clear, if you don’t smoke, don’t vape, and children should never vape. This is why the Tobacco and Vapes Bill will give us powers to crack down on child friendly flavours and packaging, and to change the way vapes are displayed in shops, measures on which we will shortly consult.
Inhaling anything other than fresh air may have long term health effects. Evidence on the harm from exposure to second-hand tobacco smoke is well established and because of its carcinogenic content there is no safe level of exposure. Breathing in other people’s tobacco smoke is known to cause a range of health issues. However, there is currently no evidence to suggest that second-hand vapour causes wider health harms in the way tobacco smoke does. Therefore, the Government has no plans to introduce restrictions on where people can vape.
However, many public venues and spaces have their own policies on vaping. For example, most hospitals and public transport have banned vaping. Employers or operators of indoor spaces would be within their rights to implement policies banning the use of vapes in their premises and many do so.
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many nurses have worked in NHS community health services on average in each of the last 10 years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England publishes Hospital and Community Health Services workforce statistics for England. These include staff working for hospital trusts and integrated care boards, but excludes staff working for other providers such as in primary care, general practice or social care. This data is drawn from the Electronic Staff Record, the human resources system for the National Health Service.
The latest statistics on NHS nursing workforce by area of nursing and care setting can be found in the link below within the ‘Nurses by Setting’ worksheet:
Within this data there are nurses working in community settings within several staff groups including community health nurses, community learning disability nurses, community mental health nurses, and as health visitors.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will have discussions with NHS England on the effectiveness of its Commercial Framework in tackling challenges presented by the appraisal and reimbursement system when applied to combination medicines and medicines with multiple indications.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
As part of the 2024 voluntary scheme for branded medicines pricing, access, and growth, NHS England has committed to undertake two consultations on its Commercial Framework for New Medicines. The first of these will be launched in summer 2024 and will align with the Competition and Markets Authority’s (CMA) statement on combination medicines. In addition, it will be more explicit about the approach taken for assessing the eligibility of medicines treating multiple indications to qualify for indication specific pricing mechanisms.
Following the first consultation, a revised framework will be published by the end of 2024, and engagement with pharmaceutical companies and patient groups on these issues is already taking place.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2024 to Question 15636 on Blood Cancer: Drugs, on what date her Department first became aware of challenges presented by the appraisal of combination therapies; and what solutions her Department is considering with NHS England to ensure continued equal access to combination medicines for multiple myeloma across the UK.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England, the National Institute for Health and Care Excellence (NICE), and the Association of the British Pharmaceutical Industry (ABPI) worked closely with the Competition and Markets Authority (CMA) over a number of years on the CMA’s statement on combination therapies, published in November 2023.
The steps taken by the CMA provide a clear commercial position that means that deals involving multiple drugs licensed by different companies can now be agreed under specific circumstances. This has been welcomed by the ABPI as an opportunity to unlock the door to more transformative combination therapies on the National Health Service.
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group have been sold in the UK.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department and NHS England do not hold information on the sales within the United Kingdom of the non-invasive pre-natal tests branded as NIFTY, manufactured by BGI Group. The NHS Supply Chain, who manage the sourcing, delivery, and supply of healthcare products, services, and food for National Health Service trusts and healthcare organisations across England, develop procurement frameworks which enable NHS organisations to buy goods and services from suppliers. NHS Supply Chain has confirmed that non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group, are not on their procurement framework.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of a full advertising ban on companies promoting vaping products.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The health advice is clear, if you don’t smoke, don’t vape and children should never vape. Advertising of vapes is already restricted by existing regulations. This includes a ban on advertising on television and radio, and through internet advertising, or commercial email. However, products can still be promoted elsewhere, such as on digital billboards.
Whilst we are not currently planning on making any further changes to the rules regarding vape advertising, we are taking action to protect children from the harms of vaping by taking new regulation making powers that can be used to limit vape flavours, how vapes are packaged, and where and how they can be displayed in retail settings. Collectively, these actions will reduce the appeal and accessibility of vapes to children, whilst ensuring vapes remain an effective smoking cessation tool for adult smokers.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the risk of people moving from non-nicotine to nicotine vapes.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Our health advice regarding vapes covers both non-nicotine as well as nicotine vapes, that while vaping can play a useful role in helping adult smokers to quit, non-smokers and children should never vape. The long-term health impacts of vaping are unknown, and the nicotine contained within nicotine vapes can be highly addictive.
We recognise the risk of non-nicotine vapes being used as a gateway to nicotine vapes by children. That is why the Tobacco and Vapes Bill includes new regulation making powers that will cover all vapes, nicotine as well as non-nicotine, to reduce their appeal and availability to children and non-smokers.